Lantheus Holdings, Inc. (NASDAQ:LNTH) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) have received an average recommendation of “Moderate Buy” from the seven analysts that are presently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a hold rating and six have given a buy rating to the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $99.17.

A number of research analysts have issued reports on the stock. Mizuho boosted their price objective on shares of Lantheus from $90.00 to $100.00 and gave the company a “buy” rating in a research report on Friday, May 3rd. JMP Securities reiterated a “market outperform” rating and issued a $100.00 price target on shares of Lantheus in a research note on Friday, February 23rd. B. Riley lifted their price objective on Lantheus from $95.00 to $99.00 and gave the company a “buy” rating in a research note on Thursday, April 18th. Truist Financial upped their price target on shares of Lantheus from $82.00 to $96.00 and gave the stock a “buy” rating in a research note on Friday, May 3rd. Finally, StockNews.com lowered shares of Lantheus from a “buy” rating to a “hold” rating in a research note on Friday, May 3rd.

Lantheus Stock Down 2.0 %

Shares of NASDAQ LNTH opened at $74.51 on Thursday. The company has a market cap of $5.16 billion, a price-to-earnings ratio of 11.38 and a beta of 0.52. The company has a quick ratio of 4.55, a current ratio of 4.84 and a debt-to-equity ratio of 0.59. The firm’s fifty day moving average is $63.16 and its 200 day moving average is $62.88. Lantheus has a 52 week low of $50.20 and a 52 week high of $100.85.

Lantheus (NASDAQ:LNTH) last issued its quarterly earnings data on Thursday, February 22nd. The medical equipment provider reported $1.59 EPS for the quarter, beating the consensus estimate of $1.33 by $0.26. Lantheus had a net margin of 33.72% and a return on equity of 54.10%. The firm had revenue of $354.00 million during the quarter, compared to the consensus estimate of $350.44 million. On average, equities research analysts expect that Lantheus will post 5.96 earnings per share for the current year.

Insider Activity

In related news, major shareholder Lantheus Alpha Therapy, Llc bought 60,431,039 shares of the business’s stock in a transaction on Wednesday, March 6th. The stock was acquired at an average price of $0.95 per share, with a total value of $57,409,487.05. Following the transaction, the insider now owns 116,773,394 shares in the company, valued at approximately $110,934,724.30. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other news, Director Mary Anne Heino sold 93,863 shares of Lantheus stock in a transaction on Monday, March 4th. The shares were sold at an average price of $65.31, for a total transaction of $6,130,192.53. Following the transaction, the director now owns 251,643 shares in the company, valued at approximately $16,434,804.33. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Lantheus Alpha Therapy, Llc acquired 60,431,039 shares of Lantheus stock in a transaction dated Wednesday, March 6th. The stock was bought at an average price of $0.95 per share, with a total value of $57,409,487.05. Following the completion of the purchase, the insider now directly owns 116,773,394 shares in the company, valued at $110,934,724.30. The disclosure for this purchase can be found here. Insiders sold 94,545 shares of company stock valued at $6,169,936 over the last three months. Insiders own 2.10% of the company’s stock.

Institutional Trading of Lantheus

Several hedge funds have recently bought and sold shares of LNTH. William Blair Investment Management LLC increased its holdings in Lantheus by 0.6% in the 1st quarter. William Blair Investment Management LLC now owns 559,834 shares of the medical equipment provider’s stock worth $34,844,000 after acquiring an additional 3,124 shares in the last quarter. ProShare Advisors LLC raised its position in shares of Lantheus by 4.7% during the 1st quarter. ProShare Advisors LLC now owns 15,567 shares of the medical equipment provider’s stock valued at $969,000 after purchasing an additional 698 shares during the period. Russell Investments Group Ltd. lifted its stake in shares of Lantheus by 10.4% during the 1st quarter. Russell Investments Group Ltd. now owns 37,708 shares of the medical equipment provider’s stock valued at $2,347,000 after buying an additional 3,560 shares in the last quarter. Headlands Technologies LLC bought a new position in Lantheus in the 1st quarter worth $105,000. Finally, Empowered Funds LLC purchased a new stake in Lantheus in the 1st quarter worth $2,358,000. Institutional investors own 99.06% of the company’s stock.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.